All Products
Also known as
PDE5Is, Phosphodiesterase-5 inhibitors, cGMP-specific phosphodiesterase type 5 inhibitors, Erectile dysfunction medications, Anti-impotence agents, Selective PDE5 inhibitors
Definition
Phosphodiesterase type 5 (PDE5) inhibitors are a class of medications that selectively block the phosphodiesterase type 5 enzyme, which is predominantly found in the corpus cavernosum of the penis and the vasculature of the lungs. These drugs function by preventing the degradation of cyclic guanosine monophosphate (cGMP), thereby prolonging the action of nitric oxide (NO) and enhancing vasodilation in specific tissues.1
The mechanism of action involves inhibiting the catalytic site of PDE5 that normally degrades cGMP. After sexual stimulation, nerve impulses release neurotransmitters in the corpora cavernosa, causing the production of nitric oxide by endothelial cells. This nitric oxide diffuses into adjacent smooth muscle cells and stimulates the formation of cGMP, leading to vasodilation and increased penile blood flow.2 PDE5 inhibitors potentiate these endogenous increases in cGMP by inhibiting its breakdown, resulting in prolonged erection.3
In addition to treating erectile dysfunction, these medications have demonstrated efficacy in managing pulmonary arterial hypertension by causing vasodilation in the pulmonary vasculature, thereby decreasing pulmonary vascular resistance and improving exercise capacity.4 They have also shown potential benefits in other conditions such as lower urinary tract symptoms associated with benign prostatic hyperplasia, Raynaud’s phenomenon, and high-altitude pulmonary edema.5
Clinical Context
PDE5 inhibitors are primarily recommended as first-line treatment for erectile dysfunction (ED) due to psychogenic, vascular, and neuropathic causes when combined with etiology-specific therapy.1 The discovery of these medications revolutionized ED treatment, offering a non-invasive, effective option for millions of men worldwide. Current estimates suggest that approximately 320 million men will encounter erectile dysfunction by 2025.2
These medications are also indicated for idiopathic pulmonary hypertension, particularly in patients with NYHA class 2 or 3 with negative acute vasodilator response. They are not recommended for patients with NYHA class 4, where prostacyclin agonists like epoprostenol and iloprost are more appropriate.3
PDE5 inhibitors effectively manage premature ejaculation associated with erectile dysfunction by increasing ejaculatory latency through inhibition of PDE5 receptors in the contractile tissue of the male reproductive tract.4 Additionally, they have shown efficacy in treating high altitude illness by reducing pulmonary hypertension in people with altitude-induced high pulmonary systolic arterial pressure.5
Early use of sildenafil after radical prostatectomy has demonstrated benefits in treating post-surgical ED due to neuro-regenerative effects on the cavernous nerve, which is often damaged during the procedure.6 For patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia with concomitant ED, these drugs reduce symptoms of hesitancy, urgency, and frequency.7
Patient selection criteria include careful evaluation of cardiovascular status, as these medications are contraindicated in patients taking nitrates due to the risk of severe hypotension. They should be used with caution in patients with recent myocardial infarction, stroke, life-threatening arrhythmias, or unstable angina.8 Dosage adjustments are necessary for patients with hepatic or renal impairment.9
The expected outcomes of PDE5 inhibitor therapy include improved erectile function, enhanced quality of life, and increased satisfaction with sexual activity. Success rates range from 65-80% in general ED populations, with variations based on etiology and comorbidities.10 Treatment failure may necessitate consideration of alternative approaches such as intracavernosal injections, vacuum devices, or penile prostheses.